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Abstract Inthepresenttrial, we comparedthebroncholyticefficacyofthe combinationtherapywith 50 mg salmeter-
ol + 250 mg fluticasone and 12 mg formoterol + 400 mg budesonide, both in a single inhaler device, in 16 patients with
moderate-to-severe COPD.The study was performed using a single-blind crossover randomized study.Lung function,
pulse oximetry (SpO2) andheartrateweremonitoredbefore and15, 30,60,120,180, 240, 300, 360,480,600, and 720min
after bronchodilator inhalation.Both combinations were effective in reducing airflow obstruction. FEV1AUC0^12 h was
2.83 l (95% CI: 2.13^3.54) after salmeterol/fluticasone and 2.57 l (95% CI:1.97^3.2) after formoterol/budesonide. Formo-
terol/budesonide elicited the mean maximum improvement in FEV1 above baseline after 120min (0.29 l; 95% CI: 0.21^
0.37) and salmeterol/fluticasone after 300min (0.32 l; 95% CI: 0.23^0.41). At 720min, the increase in FEV1over baseline
valueswas 0.10 l (95%CI: 0.07^0.12) after salmeterol/fluticasone and 0.10 l (95%CI: 0.07^0.13) after formoterol/budesonide.
Themeanpeakincreaseinheartrateoccurred 300minafter formoterol/budesonide (1.5 b/min; 95%CIF2.3 to 5.3) and
360min after salmeterol/fluticasone (2.6 b/min; 95% CIF1.9 to 7.0). Sp02 didnotchange.All differencesbetween salme-
terol/fluticasone and formoterol/budesonidewere not significant (P40.05) exceptthose in FEV1at120 and 360 min.The
results indicate that an inhaled combinationtherapywith a long-acting b2-agonist and an inhaled corticosteroid appears
to be effective in improving airway limitation after acute administration in patients suffering from COPD.r 2002 Elsevier
Science Ltd.Allrights reserved.
doi:10.1053/rmed 2002.1455, available online athttp://www.sciencedirect.comINTRODUCTION
The GOLD guidelines suggest the use of long-acting b2-
agonists and inhaled corticosteroids in the management
of stable COPD (1). Long-acting b2-agonists are recom-
mended as a ¢rst-line regular bronchodilator. Inhaled
corticosteroids are only proposed in patients who have
signi¢cant symptoms and a documented lung function
response or in those with an FEV1o50% and a history
of exacerbations.Received 23 September 2002, accepted in revised form 24 September
2002.
Correspondence should be addressed to:Dr.Mario Cazzola,Via del
ParcoMargherita 24, 80121Napoli, Italy, Fax +39 081404188,
E-mail: mcazzola@qubisoft.itIn these last years, an increasing documentation
shows that the combination of a long acting b2-adreno-
ceptor agonist bronchodilator and an inhaled cor-
ticosteroid targets both the obstruction of airways
(2) and the underlying in£ammation of COPD (3,4).
A 3-year retrospective study of COPD patients mana-
ged in primary care concluded that regular use of
salmeterol and £uticasone alone or in combination
was associated with signi¢cantly greater survival of
COPD patients managed in primary care (5). For
this reason, the salmeterol/£uticasone and formote-
rol/budesonide combinations in single inhalers are
undergoing review for the long-term, maintenance
treatment of adults with COPD (6,7), but no study
has compared these two combinations in this type of
patient.
454 RESPIRATORYMEDICINEIn the present trial, we compared the acute broncho-
lytic e⁄cacy of salmeterol/£uticasone and formoterol/
budesonide, both in a single inhaler device, in patients
with COPD.
PATIENTSANDMETHODS
We assessed 16 out-patients with coexisting moderate-
to-severe COPD [baseline FEV1 (l) = 1.327 0.16], but in
a stable phase of disease, who gave their informed con-
sent. All ful¢lled the criteria proposed by the American
Thoracic Society (8) i.e. they were 4 50 years of age,
current or former smokers (410 pack-years) without a
history of asthmatic attacks, reporting chronic cough
with or without sputum production and/or dyspnea
when walking quietly on level ground, or both; they had
had no change in symptom severity or treatment in the
preceding 4 weeks, had shown no signs of a respiratory
tract infection in the month preceding or during the
trial, had not been taking oral or inhaled corticosteroids
for at least 3months andhad anFEV1o65%ofpredicted
normal and an FVC o70% after bronchodilators had
been withheld for 24h, and a best post-bronchodilator
FEV1/FVC of less than 0.7. Patients with allergic rhinitis,
atopy, positive skin test or with a total blood eosinophil
count over 400mm3 were excluded. Patients were also
excludedif theyhad any coexisting cardiovascular or lung
disorder. Table 1 outlines the baseline characteristics of
the population studied.
All patients were in regular treatment with a long-
acting b2-agonist but notwith an inhaled corticosteroid.
No oral bronchodilator was permitted for I weekbeforeTABLE 1. Anthropometric data andpulmonary function of pat
Patient Sex Age(year) Smoker FEV1 (% p
1 F 65 Yes 4
2 M 68 Yes 3
3 M 73 Ex 5
4 M 69 Yes 4
5 M 65 Ex 6
6 M 68 Yes 6
7 M 71 Ex 6
8 M 70 Ex 4
9 M 63 Ex 4
10 M 59 Ex 6
11 M 64 Ex 5
12 M 67 Ex 4
13 M 72 Ex 4
14 M 75 Yes 5
15 F 61 Ex 2
16 M 64 Ex 4and during the study, whereas inhaled short-acting
bronchodilator drugs and inhaled long-acting bronchodi-
lator agentswere not permitted for at least12h and 24h
prior to each test, respectively. Consumption of cola
drinks, co¡ee, tea, and smoking in the hours before and
during the investigationwere also avoided.
The study was performed using a single-blind cross-
over randomized study. Each patient inhaled in two non-
consecutive days 50mg salmeterol/250mg £uticasone
(Seretide Diskus) or12mg formoterol/400mgbudesonide
(Symbicort Turbuhaler).
Lung function, pulse oximetry (SpO2), and heart rate
weremonitored before and15, 30, 60,120,180, 240, 300,
360, 480, 600, and 720min after single combination inha-
lation. Spirometric testing was performed according to
theprocedures described in theAmericanThoracic Soci-
ety’s1987 update (9).Three acceptable forced expiratory
maneuvers were performed in order to obtain two re-
producible results for FVC and FEV1. The highest FEV1
obtained from one or the other of the reproducible
curves, was kept for analysis.
The change in FEV1 was chosen as the primary out-
come variable to demonstrate bronchodilation. Re-
sponses to the treatments were evaluated in a blinded
fashion. The functional indices’ increases from baseline
after salmeterol/£uticasone and formoterol/budesonide
were assessed.Mean responses were compared by mul-
tifactorial analysis of variance (ANOVA) to establish any
signi¢cant overall e¡ect between treatments on each
day. In thepresence of a signi¢cantoverall ANOVA,Dun-
can’s multiple range testing with 95% con¢dence limits
was used to identify where di¡erences were signi¢cant.ients
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FIG. 2. Changes from baseline in IC after inhalation of 50 mg
salmeterol/250 mg £uticasone or 12 mg formoterol/400 mg bu-
desonide.Values aremeans7 SE.
FIG. 3. AUC0^12 h of changes in FEV1 induced by inhalation of
50 mg salmeterol/250 mg £uticasone or 12 mg formoterol/400
mg budesonide.Values aremeans7 SE.Po0.05
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signi¢cance for all tests.
RESULTS
The overall e¡ect of both salmeterol/£uticasone and for-
moterol/budesonide on FEV1 was signi¢cant (Po0.001)
(Fig. 1). Formoterol/budesonide elicited the mean maxi-
mum improvement in FEV1 above baseline after 120min
(0.29 l; 95% CI: 0.21^0.37) and salmeterol/£uticasone
after 300min (0.32 l; 95% CI: 0.23^0.41). At 720min, the
increase in FEV1 over baseline values was 0.10 l (95% CI:
0.07^0.12) after salmeterol/£uticasone and 0.10 l (95% CI:
0.07^0.13) after formoterol/budesonide. The di¡erence
between salmeterol/£uticasone and formoterol/budeso-
nidewas statistically signi¢cant (Po0.05) only at120 and
360 min.The tendency of the response coursewas simi-
lar for IC (Fig. 2), but the di¡erence between salmeterol/
£uticasone and formoterol/budesonidewas never signi¢-
cant (P40.05).
AUC0^12h of changes in FEV1was 2.83 l (95% CI: 2.13^
3.54) after salmeterol/£uticasone and 2.57 l (95% CI:
1.97^3.2) after formoterol/budesonide (Fig. 3).The di¡er-
ence (0.25 l; 95% CI:0.49 to 0.98) was not statistically
signi¢cant (Po0.486).
Mean peak increase in heart rate occurred 300min
after formoterol/budesonide (1.5 b/min; 95% CIF2.3 to
5.3) and 360min after salmeterol/£uticasone (2.6 b/min;
95%CIF1.9 to 7.0) (Fig.4).The di¡erencebetween salme-
terol/£uticasone and formoterol/budesonide was never
signi¢cant (P40.05). SpO2 did not change.
DISCUSSION
Long-acting b2-agonists have been shown to be e¡ective
¢rst-line bronchodilators in COPD (10,11), whereas in-
haled corticosteroids seem to reduce the frequency
and/or severity of exacerbations in COPD patients (12).FIG. 1. Changes frombaseline in FEV1after inhalation of 50 mg
salmeterol/250 mg £uticasone or 12 mg formoterol/400 mg bu-
desonide.Values are means 7 SE. *Po0.05 salmeterol/£utica-
sone vs. formoterol/budesonide.
FIG. 4. Changes from baseline in heart rate after inhalaton of
50 mg salmeterol/250 mg £uticasone or 12 mg formoterol/400
mg budesonide.Values aremeans7 SE.In particular, it must be highlighted that, although there
are criticisms on the role of inhaled corticosteroids in
the treatmentof COPD, several solid studies have clearly
documented that they are bene¢cial in COPD patients
with a rather severe clinical condition, those who more
frequently ask for a pharmacological help (13,14). There-
fore, the combination of a long-acting b2-adrenoceptor
agonist bronchodilator and an inhaled corticosteroid
has a logical role in the treatmentofmoderate-to-severe
456 RESPIRATORYMEDICINECOPD, o¡ering the advantage of increased convenience
and possibly improved compliance.
The results of this study indicate that an acute
administration of an inhaled combination therapy with
a long-acting b2-agonist and an inhaled corticosteroid
appears to be e¡ective and safe in improving airway
limitation in patients su¡ering from COPD and under
regular treatment with a long-acting b2-agonist. Our
data con¢rm that both 50mg salmeterol and 12mg
formoterol induce a good and long-lasting bronchodila-
tion in patients su¡ering from stable COPD after a
single administration (15,16), and show that the addition
of an inhaled corticosteroid does not di¡erentiate
the bronchodilator e¡ects of these two long acting
b2-agonists.
Unfortunately, our study does not permit to establish
whether or not the acute addition of an inhaled corticos-
teroid ampli¢es the response to long-acting b2-agonist.
The lackof this information limits thevalue of thesedata.
However, experience shows that it is unlikely that a pa-
tient su¡ering from COPDwill accept to participate in a
study,which schedules spirometric testing for12h in four
di¡erentdays.Therefore, a better way for appraising the
value of the addition of an inhaled corticosteroid is that
to compare, in the samepatient only, a single long-acting
b2-agonists and its combination with the topical steroid.
But this type of designwould not have allowed the com-
parison of the two combinations that was the true pur-
pose of this search.
Theoretically, it is possible that the steroid compo-
nent can enhance the e¡ect of the b2-receptor compo-
nent, since the glucocorticoid can upregulate b2-
receptor expression (17,18). In e¡ect, a topical steroid
that is administered for a brief period may improve the
degree of airway obstruction even in severely ill, ventila-
tor-dependent COPD patients with chronic respiratory
failure who are in stable condition (19). Moreover, Sza-
franskiet al. (20) have documented that1-year treatment
with budesonide/formoterol treatment increased FEV1
by 15% vs. placebo, 9% vs. budesonide (both Po0.001),
and1% vs. formoterol (non-signi¢cant) in patients su¡er-
ing frommoderate-to-severe COPD.
In asthmatic patients, budesonide/formoterol has de-
monstrated a faster onset of action than salmeterol/£u-
ticasone (21). The authors of the study have suggested
that the presence of budesonide could have contributed
to some of the observedbronchodilation inducedby for-
moterol, but they have not explained why the presence
of £uticasone did not in£uence the bronchodilation eli-
cited by salmeterol. In the present study, we have ob-
served a trend for a faster onset of action of
budesonide/formoterol, but the di¡erences between bu-
desonide/formoterol and salmeterol/£uticasone were
only signi¢cant after 120min. In our opinion, the impor-
tance of a fast onset of action in patients su¡ering from
stable COPD is questionable because the most impor-tant need for these patients is a sustained bronchodila-
tion.
In this study, both salmeterol/£uticasone and budeso-
nide/formoterol have shown to be able to induce such
an e¡ect, although it must be highlighted that AUC0^12h
changes in FEV1was higher after salmeterol/£uticasone
than after formoterol/budesonide but the di¡erence
was not statistically signi¢cant. We cannot exclude
that the lack of signi¢cance was due to the small
sample, so the possibility of a type II error was high.
However, this was a pilot study, and for this reason we
were unable to calculate the sample size. In theory,
we could base power calculations on results obtained
with acute administration of formoterol and salmeterol
in COPD and on the minimum useful clinical improve-
ment thatmight be expected, but this procedure has no
scienti¢c basis.
The documentation that the addition of an inhaled
corticosteroid does not modify the non-pulmonary re-
sponses to a long-acting b2-agonists is an important ¢nd-
ing of our study. It has been shown that concomitant
therapy with inhaled budesonide resensitised the re-
sponse of cardiacb2-adrenoceptors to salbutamol in sub-
jectswhowere receiving regular twice-daily formoterol
(22). Obviously, a single administration of a b2-agonists
cannot induce tachyphylaxis, but our patients were un-
der regular treatment with a long-acting b2-agonist.
Therefore, we cannot exclude that some of them pre-
sented tolerance to the non-pulmonary e¡ects induced
by these agents, and the restored heart b-adrenergic re-
sponsiveness was a possibility. In any case, these data
con¢rm results of a previous study, which showed that
adding the recommended dose of formoterol to an in-
haled corticosteroid therapy does not induce signi¢cant
cardiac undesirable e¡ects (23).
This small study seems to indicate that there is no sub-
stantial di¡erence between salmeterol/£uticasone and
formoterol/budesonide in patients with COPD when
these combinations are prescribed at the dosages re-
commended for this pathology. Obviously, only a larger
study with adequate sample size and duration of treat-
ment (at least six months) will establish if this similitude
is real. Probably, this study will have other outcomes
than the simple change in FEV1.
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